Adaptimmune Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Operating Leases

Operating Leases

12 Months Ended

Dec. 31, 2019

Operating leases

Operating leases

Note 8 — Operating leases

The following table shows the lease costs for the year ended December 31, 2019 (in thousands):


	Year ended
	December 31,
	2019
Lease cost:
Operating lease cost	$	4,017
Short-term lease cost		319
	$	4,336

	Year ended
	December 31,
	2019
Other information:
Operating cash flows from operating leases (in thousands)	$	4,063

	December 31,
	2019

Weighted-average remaining lease term - operating leases	7.3 years
Weighted-average discount rate - operating leases	7.2%

The maturities of operating lease liabilities as of December 31, 2019 are as follows (in thousands):


	Operating leases

2020	$	4,191
2021		4,234
2022		4,237
2023		4,004
2024		3,936
after 2024		12,748
Total lease payments		33,350
Less: Imputed interest		(7,890)
Present value of lease liability	$	25,460

The Company has operating leases in relation to property for office and research facilities. The maximum lease term without activation of termination options is to 2041.